Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 4/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21214401 | 1.00 | KDM4E (0.46) | KDM4EGAASMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL19226319 | 1.00 | KDM4E (0.46) | KDM4EGAASMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL18782450 | 0.90 | KDM4E (0.44) | KDM4EHRH3HTR7 | |
| SCHEMBL17888267 | 0.81 | CARM1 (0.60) | KDM4EGAASMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL17277592 | 0.81 | CARM1 (0.60) | KDM4EGAASMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL17888266 | 0.81 | CARM1 (0.60) | KDM4EGAASMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL18233590 | 0.81 | CARM1 (0.35) | HRH3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL21078331 | 0.80 | KDM4E (0.47) | KDM4EGAASMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL18774762 | 0.79 | USP2 (0.36) | KDM4EGAASMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL19226608 | 0.79 | USP2 (0.36) | KDM4EGAASMN1; SMN2HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | KDM4E 2788/4885GAA 2777/4885SMN1; SMN2 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.